Allo-HSCT May Be Effective for Patients With Hepatosplenic T-Cell Lymphoma
Researchers sought to determine whether allo-HSCT would be helpful in treating patients with hepatosplenic T-cell lymphoma.
Researchers sought to determine whether allo-HSCT would be helpful in treating patients with hepatosplenic T-cell lymphoma.
Overall survival was longer with ablative radiotherapy than with conventional radiotherapy.
Researchers sought to determine whether levels of different DNA demethylation intermediates would be associated with AML or MDS.
Researchers sought to determine whether treatment of CD30-positive lymphomas with an innate cell engager would be effective.